Comparative Pharmacology
Head-to-head clinical analysis: COTRIM versus CUBICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COTRIM versus CUBICIN.
COTRIM vs CUBICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COTRIM is a combination of trimethoprim and sulfamethoxazole; sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, sequentially blocking bacterial folate synthesis.
Cubicin is a lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and inhibition of protein, DNA, and RNA synthesis, leading to bacterial cell death.
1 double-strength tablet (160 mg trimethoprim + 800 mg sulfamethoxazole) orally every 12 hours for 5-14 days; 15-20 mg/kg/day (based on trimethoprim) IV divided every 6-8 hours for severe infections.
4-6 mg/kg IV once daily for complicated skin infections; 6 mg/kg IV once daily for Staphylococcus aureus bloodstream infections (including right-sided endocarditis); infuse over 2 minutes or 30 minutes.
None Documented
None Documented
Sulfamethoxazole: 9-11 hours (normal renal function); trimethoprim: 8-10 hours. Extended in renal impairment (SMX up to 30h, TMP up to 24h).
Terminal elimination half-life is about 8-9 hours (mean 8.1 hours) in patients with normal renal function; prolonged to 27-35 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-70% unchanged sulfamethoxazole, 15-30% N4-acetylated metabolite; trimethoprim: 50-60% unchanged, 10-20% metabolites. Biliary/fecal: minimal.
Renal excretion of unchanged drug accounts for approximately 80% of the administered dose; minor fecal excretion (<5%) via biliary elimination.
Category C
Category C
Antibiotic
Antibiotic